FR3122084B1 - Composition cosmétique ou pharmaceutique caractérisée par une association de bioactifs sélectionnés à partir de graines deGlycine max pour son utilisation dans la modulation du microbiote intestinal et cutanée et l’équilibre de l’axe intestin-peau-cerveau. - Google Patents

Composition cosmétique ou pharmaceutique caractérisée par une association de bioactifs sélectionnés à partir de graines deGlycine max pour son utilisation dans la modulation du microbiote intestinal et cutanée et l’équilibre de l’axe intestin-peau-cerveau. Download PDF

Info

Publication number
FR3122084B1
FR3122084B1 FR2104166A FR2104166A FR3122084B1 FR 3122084 B1 FR3122084 B1 FR 3122084B1 FR 2104166 A FR2104166 A FR 2104166A FR 2104166 A FR2104166 A FR 2104166A FR 3122084 B1 FR3122084 B1 FR 3122084B1
Authority
FR
France
Prior art keywords
skin
bioactives
intestine
intestinal
cosmetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2104166A
Other languages
English (en)
Other versions
FR3122084A1 (fr
Inventor
Mizuho Nasu
Bejit Ideas
Yuki Murata
Jean-Yves Bruxer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirei International Ltd
Original Assignee
Mirei International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirei International Ltd filed Critical Mirei International Ltd
Priority to FR2104166A priority Critical patent/FR3122084B1/fr
Publication of FR3122084A1 publication Critical patent/FR3122084A1/fr
Application granted granted Critical
Publication of FR3122084B1 publication Critical patent/FR3122084B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composition cosmétique ou pharmaceutique comprenant une association de bioactifs sélectionnés à partir de graines de Glycine max, parmi le groupe : citrulline, taurine, proline, phosphatidylsérine, GABA, ornithine, histidine, leucine, lipoteichoic acid, biotine, cystéine, éctoïne, acide malique, pour leur utilisation dans le traitement ou la prévention de la dysbiose intestinale et/ou cutanée, l’équilibre de l’axe intestin-peau-cerveau et pour l’amélioration des troubles de l’humeur.
FR2104166A 2021-04-21 2021-04-21 Composition cosmétique ou pharmaceutique caractérisée par une association de bioactifs sélectionnés à partir de graines deGlycine max pour son utilisation dans la modulation du microbiote intestinal et cutanée et l’équilibre de l’axe intestin-peau-cerveau. Active FR3122084B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR2104166A FR3122084B1 (fr) 2021-04-21 2021-04-21 Composition cosmétique ou pharmaceutique caractérisée par une association de bioactifs sélectionnés à partir de graines deGlycine max pour son utilisation dans la modulation du microbiote intestinal et cutanée et l’équilibre de l’axe intestin-peau-cerveau.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2104166A FR3122084B1 (fr) 2021-04-21 2021-04-21 Composition cosmétique ou pharmaceutique caractérisée par une association de bioactifs sélectionnés à partir de graines deGlycine max pour son utilisation dans la modulation du microbiote intestinal et cutanée et l’équilibre de l’axe intestin-peau-cerveau.
FR2104166 2021-04-21

Publications (2)

Publication Number Publication Date
FR3122084A1 FR3122084A1 (fr) 2022-10-28
FR3122084B1 true FR3122084B1 (fr) 2023-10-27

Family

ID=77021427

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2104166A Active FR3122084B1 (fr) 2021-04-21 2021-04-21 Composition cosmétique ou pharmaceutique caractérisée par une association de bioactifs sélectionnés à partir de graines deGlycine max pour son utilisation dans la modulation du microbiote intestinal et cutanée et l’équilibre de l’axe intestin-peau-cerveau.

Country Status (1)

Country Link
FR (1) FR3122084B1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2136825T1 (sl) 2007-03-01 2014-04-30 Probi Ab Uporaba lactobacillus plantarium za povečanje bakterijske raznolikosti
EP2983662A4 (fr) 2013-03-15 2016-09-21 MicroBiome Therapeutics LLC Fibre de cosse de soja activée
WO2015159125A1 (fr) 2014-04-15 2015-10-22 Compagnie Gervais Danone Utilisation de lactobacillus rhamnosus pour favoriser le rétablissement de la diversité du microbiote intestinal d'un sujet après dysbiose provoquée par des antibiotiques
CN107648057A (zh) * 2017-10-21 2018-02-02 诺斯贝尔化妆品股份有限公司 一种长效保湿修复生物纤维面膜
CN110339206A (zh) * 2019-07-30 2019-10-18 岳茂兴 一种用于治疗顽固性痤疮的药物组合物及其应用

Also Published As

Publication number Publication date
FR3122084A1 (fr) 2022-10-28

Similar Documents

Publication Publication Date Title
Fang et al. Polyphenol-mediated redox-active hydrogel with H2S gaseous-bioelectric coupling for periodontal bone healing in diabetes
Reichl et al. Cytotoxicity of dental composite (co) monomers and the amalgam component Hg2+ in human gingival fibroblasts
MA54231A (fr) Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine
Kuang et al. Metformin prevents against oxidative stress-induced senescence in human periodontal ligament cells
Wang et al. Novel metformin-containing resin promotes odontogenic differentiation and mineral synthesis of dental pulp stem cells
Bukhari et al. Synergistic effects of combined therapy of curcumin and Fructus Ligustri Lucidi for treatment of osteoporosis: cellular and molecular evidence of enhanced bone formation
Liu et al. In vitro cell behaviors of bone mesenchymal stem cells derived from normal and postmenopausal osteoporotic rats
WO2019108809A3 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
Niu et al. Nardosinone suppresses RANKL-induced osteoclastogenesis and attenuates lipopolysaccharide-induced alveolar bone resorption
WO2018208011A3 (fr) PEPTIDE BIOCOMPATIBLE SUPPRIMANT L'AGGRÉGATION DE LA PROTÉINE β-AMYLOÏDE
FR3122084B1 (fr) Composition cosmétique ou pharmaceutique caractérisée par une association de bioactifs sélectionnés à partir de graines deGlycine max pour son utilisation dans la modulation du microbiote intestinal et cutanée et l’équilibre de l’axe intestin-peau-cerveau.
Perchyonok et al. Insights into chitosan hydrogels on dentine bond strength and cytotoxicity
Khan et al. Absence of glia maturation factor protects dopaminergic neurons and improves motor behavior in mouse model of parkinsonism
Liu et al. Bioinspired hydrogel for sustained minocycline release: A superior periodontitis solution
FR2913885B1 (fr) Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines
Huang et al. Prevention of the epoxy resin-based root canal sealers-induced cyclooxygenase-2 expression and cytotoxicity of human osteoblastic cells by various antioxidants
Siddappa et al. Engineered immunomodulatory nanoparticles inhibit root resorption and ankylosis
Thu et al. Exploring molecular mechanism of bone-forming capacity of Eurycoma longifolia: Evidence of enhanced expression of bone-related biomarkers
Li et al. Injectable responsive hydrogel with synergistic antibacterial and anti-inflammatory properties for enhanced periodontitis treatment
Wimolsantirungsri et al. Inhibitory effect of Thai propolis on human osteoclastogenesis
Sun et al. Cytotoxic Effects of One-step Self-etching Dental Adhesives on Human Periodontal Ligament Fibroblasts In Vitro.
Fahmy et al. Effects of histone acetyltransferase (HAT) and histone deacetylase (HDAC) inhibitors on proliferative, differentiative, and regenerative functions of Toll-like receptor 2 (TLR-2)-stimulated human dental pulp cells (hDPCs)
Olivares-Navarrete et al. Role of the N-terminal peptide of amelogenin on osteoblastic differentiation of human mesenchymal stem cells
FR2861594B1 (fr) Composition contenant un extrait de the vert et de la vitamine c
Morisbak et al. In vitro effects of dental monomer exposure-Dependence on the cell culture model

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20221028

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6